November 16, 2012 |
Diabetes prevalence rates jumped dramatically across the nation between 1995 and 2010, researchers at the U.S. Centers for Disease Control reported in Friday's edition of the Morbidity and Mortality Weekly Report . Using data from the Behavioral Risk Factor Surveillance System, an annual phone survey of adults 18 and older, the investigators found that overall, the median prevalence of diagnosed diabetes went up from 4.5% in 1995 to 8.2% in...
September 26, 2012 |
There's a lot of talk these days about the role of gut bacteria in disease and health. The latest report in that area: a study in Nature that finds differences between the bacteria growing in the guts of people who have diabetes and those who don't. The Chinese and European authors of the study used DNA analysis to figure out the bacterial populations inside 345 Chinese people. They found that people with diabetes had mild gut disturbances. They had fewer bacteria that make a compound called butyrate, for example.
August 8, 2012 |
Against the drumbeat of bad news on obesity and diabetes among children, researchers have uncovered a cause for cautious optimism: a steady and significant improvement in the cholesterol profiles of American kids over the last 20 years. The proportion of young people ages 6 to 19 with high total cholesterol dropped 28% between the two time periods sampled in the report, from 11.3% in 1988-94 down to 8.1% in 2007-10, the new study found. At the same time, the average American teen's levels of "good" HDL cholesterol, "bad" LDL cholesterol and triglycerides - dangerous fats that circulate in the bloodstream and slowly clog arteries - improved too. Scientists said they weren't sure what had led to the encouraging changes reported Tuesday in the Journal of the American Medical Assn.Use of cholesterol-lowering drugs remains rare among children, they noted.
June 30, 2012 |
Amylin Pharmaceuticals Inc., the San Diego drug maker whose treatments include the diabetes therapies Bydureon and Byetta, will be acquired by Bristol-Myers Squibb Co. for $5.3 billion in cash. Bristol-Myers agreed to pay $31 a share for Amylin, the companies said Friday in a statement. That's 10% more than the company's closing price Friday. Including Amylin's debt and a payment to Eli Lilly & Co. of about $1.7 billion, the deal is valued at about $7 billion. "We are pleased to be able to strengthen the portfolio we have built to help patients with diabetes by building on the success Amylin has had with its GLP-1 franchise," said Bristol-Myers Chief Executive Lamberto Andreotti in the statement.
June 20, 2012 |
After gastric bypass surgery, people with Type 2 diabetes often see their disease completely disappear - within weeks, before they've lost much or any weight. It doesn't work for everyone, though. What are the factors that matter? A study by a team of scientists from the University of Massachussetts looked into that. Here are their findings, which were presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery. The scientists looked at remission of diabetes in 139 patients, ages 48 to 57, who'd had gastric bypass surgery.
CALIFORNIA | LOCAL
June 18, 2012 |
Randy Muñoz glided among the guests, greeting and hugging them. They were in a posh club 54 floors above Los Angeles, and the windows looked out to a shimmering vista of lighted streets. They swirled cocktails, dined on shrimp and gyoza, soaked up a Latin trio and traded pleasantries. Then Muñoz, called on to speak, riled the serenity with a jolt of emotion. "How many of you guys have diabetes in your families? OK. Keep those hands up and look around. Look around. That's disgusting.
June 13, 2012 |
Paula Deen may be bringing more of her butter-drenched recipes to supermarkets and retailers such as Target, Wal-Mart and Kroger with the creation of her new Paula Deen Foods company. Think classic Deen creations "as well as lighter versions," according to a news release this week about the launch. The products are expected to hit shelves this fall. The Georgia-based celebrity chef is pairing up with Buffalo, N.Y.-based Nanco Group, which launched and sold Tops Friendly Markets and Wilson Farms Stores under the ownership of the Nanula family, to develop products and run quality control.
June 12, 2012 |
For Terra Hillyer, who has Type 1 diabetes, enrolling in a clinical trial for a new medical device called the artificial pancreas provided a glimpse of what life might be like without the constant checks of blood sugar levels and infusions of insulin that currently mark her days. “The first thing I do when I wake up is check my blood sugar,” Hillyer says. “It is the background noise of my life.” Except for one day recently, when the mother of two checked into the Sansum Diabetes Research Institute in Santa Barbara.
June 5, 2012 |
Want to gauge your risk for developing Type 2 diabetes? Don't just step on the scale - reach for a measuring tape too, a new study suggests. The circumference of your waist can tell you a lot about your chances of getting diabetes, according to a study published Tuesday in the journal PLoS Medicine . Health providers usually rely on body mass index to determine patients' diabetes risk, but adding waist circumference to the equation would...
June 1, 2012 |
Taking the diabetes drug pioglitazone, better known by the brand name Actos, doubles the risk of developing bladder cancer, Canadian researchers have found. In absolute terms, however, the risk remains low, the researchers found -- an extra 137 cases per 100,000 person-years. According to the National Cancer Institute, there are an estimated 70,530 cases of bladder cancer in the U.S. each year and 14,680 deaths. The U.S. Food and Drug Administration warned in June 2011 that taking Actos for at least a year increased the risk of bladder cancer by at least 40%, and ordered the drug's manufacturer, Takeda Pharmaceutical North America, to note the risk on the drug's label.